Analysts see challenges for Tetra's fragile X syndrome drug

4 May 2018

BPN14770, which is being developed by Tetra Discovery Partners for the treatment of fragile X syndrome (FXS), was granted Orphan Drug Designation by the US Food and Drug Administration in April 2018.

However, by the time this drug launches, there could be a handful of new drugs already approved for FXS, according to data and analytics company GlobalData.

Tetra is planning to initiate Phase II trials in adults with FXS and in patients with Alzheimer’s disease in second-quarter 2018 after receiving Investigational New Drug approval in March. The company intends to expand its evaluation of BPN14770 in FXS to pediatric patients later this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK